161 related articles for article (PubMed ID: 29600505)
1. The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System.
Parekh W; Streeton SE; Baker-Knight J; Montagnoli R; Nicoziani P; Marchesini G
Diabetes Ther; 2018 Jun; 9(3):1037-1047. PubMed ID: 29600505
[TBL] [Abstract][Full Text] [Related]
2. The Economic Burden of Insulin-Related Hypoglycemia in Spain.
Parekh W; Hoskins N; Baker-Knight J; Ramirez de Arellano A; Mezquita Raya P
Diabetes Ther; 2017 Aug; 8(4):899-913. PubMed ID: 28653237
[TBL] [Abstract][Full Text] [Related]
3. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the Local Impact of Hypoglycemia Tool.
Hoskins N; Tikkanen CK; Pedersen-Bjergaard U
J Med Econ; 2017 Apr; 20(4):363-370. PubMed ID: 27926814
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
[TBL] [Abstract][Full Text] [Related]
5. Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool.
Parekh WA; Ashley D; Chubb B; Gillies H; Evans M
Diabet Med; 2015 Sep; 32(9):1156-66. PubMed ID: 25816891
[TBL] [Abstract][Full Text] [Related]
6. Costs associated with emergency care and hospitalization for severe hypoglycemia.
Veronese G; Marchesini G; Forlani G; Saragoni S; Degli Esposti L; Centis E; Fabbri A;
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):345-51. PubMed ID: 26897390
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain.
Morales C; de Luis D; de Arellano AR; Ferrario MG; Lizán L
Diabetes Ther; 2015 Dec; 6(4):593-610. PubMed ID: 26589521
[TBL] [Abstract][Full Text] [Related]
8. Economic impact of hypoglycemia among insulin-treated patients with diabetes.
Sussman M; Sierra JA; Garg S; Bode B; Friedman M; Gill M; Kaufman F; Vigersky R; Menzin J
J Med Econ; 2016 Nov; 19(11):1099-1106. PubMed ID: 27292016
[TBL] [Abstract][Full Text] [Related]
9. The burden of severe hypoglycemia in type 1 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):171-177. PubMed ID: 29019269
[TBL] [Abstract][Full Text] [Related]
10. Cost calculation for a flash glucose monitoring system for UK adults with type 1 diabetes mellitus receiving intensive insulin treatment.
Hellmund R; Weitgasser R; Blissett D
Diabetes Res Clin Pract; 2018 Apr; 138():193-200. PubMed ID: 29410149
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
Weatherall J; Bloudek L; Buchs S
Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
[TBL] [Abstract][Full Text] [Related]
12. Improvement of Metabolic Control and Diabetes Management in Insulin-Treated Patients Results in Substantial Cost Savings for the German Health System.
Fritzen K; Gutschek B; Coucke B; Zakrzewska K; Hummel M; Schnell O
J Diabetes Sci Technol; 2018 Sep; 12(5):1002-1006. PubMed ID: 29436251
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
14. The burden of severe hypoglycemia in type 2 diabetes.
Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
Curr Med Res Opin; 2018 Jan; 34(1):179-186. PubMed ID: 29017368
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus.
Oyagüez I; Merino-Torres JF; Brito M; Bellido V; Cardona-Hernandez R; Gomez-Peralta F; Morales-Perez F
BMJ Open Diabetes Res Care; 2020 Jul; 8(1):. PubMed ID: 32699114
[TBL] [Abstract][Full Text] [Related]
16. The Potential Cost Implications of Averting Severe Hypoglycemic Events Requiring Hospitalization in High-Risk Adults With Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring.
Bronstone A; Graham C
J Diabetes Sci Technol; 2016 Jul; 10(4):905-13. PubMed ID: 26880392
[TBL] [Abstract][Full Text] [Related]
17. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model.
Hinahara J; Weinzimer SA; Bromley ER; Goss TF; Kendall DM; Hammer M
J Manag Care Spec Pharm; 2022 Apr; 28(4):461-472. PubMed ID: 35332789
[No Abstract] [Full Text] [Related]
18. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands.
de Groot S; Enters-Weijnen CF; Geelhoed-Duijvestijn PH; Kanters TA
BMJ Open; 2018 Mar; 8(3):e019864. PubMed ID: 29581204
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States.
Foos V; Varol N; Curtis BH; Boye KS; Grant D; Palmer JL; McEwan P
J Med Econ; 2015 Jun; 18(6):420-32. PubMed ID: 25629654
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
